{"id":"NCT00753454","sponsor":"UCB Pharma","briefTitle":"Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)","officialTitle":"A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2008-09-16","resultsPosted":"2012-06-14","lastUpdate":"2018-08-01"},"enrollment":168,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Certolizumab pegol","otherNames":["Cimzia"]}],"arms":[{"label":"CDP870","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to continue to assess the safety of certolizumab pegol in combination with methotrexate (MTX).","primaryOutcome":{"measure":"Percentage of Subjects Reporting At Least One Treatment-emergent Adverse Event (TEAE) During The Study Period","timeFrame":"From Entry Visit up to approximately 60 weeks","effectByArm":[{"arm":"CDP870","deltaMin":52.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":40,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":168},"commonTop":["Upper Respiratory Tract Infection"]}}